Alnylam Pharmaceuticals (ALNY): Can Shares Reach the $300 Analyst Target?

Key Takeaways

• The central target of $300 is the arithmetic mean of 14 current, individually attributed analyst price targets, with a wide range from $199 to $410.
• Against a latest verified price near $165, reaching $300 would require roughly an 82% advance, a very large move.
• Post-Q3 2026 target cuts dominate the picture: most firms lowered their targets in late October and early November after Amvuttra demand came in below expectations and the TRITON-CM trial was expanded.
• Supporting factors include 52% year-over-year net product revenue growth, a growing TTR franchise, a strong balance sheet, and a large untreated ATTR-CM patient population.
• Key risks include softer Amvuttra demand growth, payer and 340B rule uncertainty, competition, and a long runway before the next-generation nucresiran data read out.

Analyst Price Targets and Consensus View

Alnylam Pharmaceuticals, Inc. (ALNY), the RNA interference (RNAi) therapeutics pioneer, saw its analyst target landscape reset sharply after its October 29, 2026 third-quarter report. Reviewing 14 current targets that identify the analyst, firm, and date, the range runs from a low of $199 (Bernstein, Market Perform) to a high of $410 (Piper Sandler, Buy). The arithmetic mean of these targets is about $301, rounded to a central target of $300.

The dispersion is unusually wide, reflecting genuine disagreement. Bulls such as Barclays ($380), TD Cowen ($354), and Goldman Sachs ($320) emphasize the long-term ATTR amyloidosis opportunity. More cautious voices — Truist ($225, downgraded to Hold), Morgan Stanley ($240, Equal Weight), and Bernstein ($199, downgraded to Market Perform) — cite a less certain Amvuttra outlook and the enrollment expansion of the TRITON-CM Phase 3 trial of nucresiran. These downgrades and target cuts are materially relevant because they follow a stock that has already fallen sharply from its 52-week high near $480. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

With shares trading near $165, the $300 central target implies roughly 82% upside, a very large required move. The stock sits far below its 52-week high of roughly $480 and only modestly above its 52-week low near $149.

Fundamentals are mixed. Third-quarter 2026 net product revenue rose 52% year over year to about $1.29 billion, led by $1.13 billion of Amvuttra sales (up 65%). Yet management acknowledged that underlying Amvuttra demand growth has not met expectations and guided full-year TTR revenue toward the low end of its $4.2–$4.5 billion range. Reported GAAP net income of $2.17 billion was inflated by an approximately $1.9 billion non-cash tax benefit, so investors should focus on the operating picture rather than the headline profit.

What Could Support a Move Toward the Target

The TTR franchise remains the engine, with roughly 80% of prevalent ATTR-CM (transthyretin amyloid cardiomyopathy) patients still untreated. Amvuttra holds about 24% of total TTR-category prescriptions, and its new-to-brand share has stayed above 30%. A strong balance sheet — about $3.6 billion in cash and marketable securities — funds continued commercial investment and pipeline development, including the Huntington's disease program brezosiran and next-generation nucresiran. Reacceleration of Amvuttra demand growth, favorable resolution of the 340B reimbursement uncertainty, and positive clinical readouts would all support a higher valuation.

What Could Prevent the Target From Being Reached

The principal obstacle is Amvuttra's demand trajectory. A more restrictive UnitedHealth Medicare Advantage policy and a proposed CMS 340B rule that could reduce Part B reimbursement create near-term uncertainty around pricing, volume, and ordering patterns. Competition in ATTR-CM, a longer runway before nucresiran's potential 2030 launch, and valuation compression in a risk-off biotech tape all present headwinds. The wide analyst range — from $199 to $410 — signals that even professionals disagree substantially on whether the current reset is overdone or justified. From what I see, this uncertainty is worth monitoring closely.

Technical Levels and Market Structure

Technically, the stock has transitioned from a long-term uptrend to a downtrend in 2026, losing roughly two-thirds of its value from the high. The 52-week low near $149 stands as key support, while prior consolidation zones and the psychological $200 level represent resistance on any recovery. A durable reclaim of the $200 area would be an early signal that the post-earnings decline may be stabilizing, but the stock remains well below its longer-term trend structure.

Time Horizon and What Investors Should Monitor

Most analyst price targets reflect a roughly 12-month research horizon, though individual timelines vary. Investors should watch Amvuttra prescription and demand trends, updates on the 340B rule, the two-year HELIOS-B open-label extension data and indirect treatment comparison presented at medical meetings, and the company's 2027 product revenue guidance, now expected in mid-February rather than at the January JPMorgan conference. Any further analyst revisions around these events will shape whether the $300 central target moves up or down.

Exploring AI Daily Buy/Sell Signals

In my own research process, Tickeron's AI Daily Buy/Sell Signals have proven helpful for monitoring volatile names like this one. The tool uses artificial intelligence to generate Buy, Sell, or Hold signals based on shifting market conditions and technical behavior, which can complement manual analysis when tracking rapid target revisions and price swings.

Final Assessment

The question of whether Alnylam can reach $300 is, in essence, a question about whether Amvuttra demand reaccelerates and whether the pipeline justifies the premium bulls still assign. The $300 central target, averaging 14 analyst views spanning $199 to $410, sits roughly 82% above the current price, making it a demanding threshold rather than a modest recovery. Strong franchise growth, an underpenetrated market, and a robust balance sheet provide the foundation, while softer demand, reimbursement uncertainty, and competition weigh against a rapid advance. With analyst opinion so divided, the stock's path will likely hinge on forthcoming demand data and the February 2027 guidance update, which investors should monitor closely before drawing conclusions about the $300 level.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume